ArticleMolecular medicine (Cambridge, Mass.)2025
Mirabegron treatment reduces myofibroblasts and CXCR2 expression in adipose tissue in obesity.
Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTreatment with the β3-adrenergic receptor (AR) agonist mirabegron improves insulin sensitivity β, cell function, and glucose tolerance in individuals with obesity, without weight loss or a change in brown adipose tissue (BAT) (Finlin et al, J Clin Invest. 2020 May 1;130(5):2319-2331). Furthermore, mirabegron treatment increased protein expression of beige adipose markers and the number of anti-inflammatory macrophages, and changed the expression of genes involved in fibrosis and tissue remodeling in subcutaneous white adipose tissue (SC WAT).
methodsWe utilized RNA seq and enrichment analysis to identify biological pathways changed by mirabegron treatment in SC WAT thigh biopsies. We verified these changes by immunohistochemistry and performed mechanistic studies in differentiated human adipocytes in vitro.
resultsMirabegron treatment reduced myofibroblasts, which are fibrotic, and reduced CXCR2, which is involved in inflammation and chemotaxis, in SC WAT. Adipose tissue myofibroblasts were higher with obesity and negatively correlated with β cell function. Mirabegron inhibited TGFβ induction of the adipocyte mesenchymal transition pathway in differentiated adipocytes in vitro. Furthermore, mirabegron treatment reduced expression of snail, a transcription factor which promotes the mesenchymal transition pathway, in vitro and in vivo. We also found that mirabegron treatment reduced CXCR2 expression in SC WAT. CXCR2 was expressed by NK cells and mirabegron treatment reduced CXCR2 expression in NK cells in SC WAT.
conclusionTogether, these results suggest new mechanisms for improvement of the human SC WAT phenotype by mirabegron treatment to enhance glucose metabolism. These new mechanisms involve the reduction of myofibroblasts as well as the reduction of CXCR2 expression in NK cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.